RxDoctor Payments Data

Ilan Aharoni, MD

Gastroenterology · Orlando, FLNPI 1851423701

Payments from drug & device makers

$272,269in general payments, 2019–2025

Across 210 payments — averaging $1296.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$159K
  • Amgen$66K
  • Pfizer$25K
  • Eli Lilly$17K
  • Celltrion USA Inc.$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$257
  • plus $892 from 16 others

What the payments were for

  • Consulting fees$3,8357%
  • Speaking & faculty fees$43,57577%
  • Travel & lodging$4,2037%
  • Food & beverage$4,6248%
  • Education$220%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$272,269 in reported general payments places this provider in the 90th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$65,582
Medicare patients
266
Services billed
626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab50$1,418,088
RinvoqUpadacitinib37$394,367
EntyvioVedolizumab41$358,632
Skyrizi On-BodyRisankizumab-Rzaa17$355,613
Humira(Cf) PenAdalimumab11$147,949
SkyriziRisankizumab-Rzaa14$142,568
XifaxanRifaximin23$90,091
LinzessLinaclotide24$29,153
Mesalamine25$10,224
Dexlansoprazole DrDexlansoprazole14$4,714
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates51$3,072
Budesonide DrBudesonide13$2,102
Sucralfate12$1,374
Omeprazole44$1,029
Famotidine28$514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$135$1,418,08850 claims
AbbVieRinvoq, Skyrizi, Linzess$158,657$566,08875 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$257$358,63241 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$96$90,09123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →